Tuesday, August 26, 2008

AMAG Pharmaceuticals Receives Fast Track Designation For Ferumoxytol For Vascular-Enhanced MRI

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ferumoxytol for its development as a diagnostic agent for Vascular-Enhanced Magnetic Resonance Imaging (VE-MRI) to improve the assessment of peripheral arterial disease in patients with known or suspected chronic kidney disease (CKD). Continue reading ...

The following summarizes recent efforts and initiatives that seek to reduce racial health disparities. Charles County, Md.: Ministers Alliance of Charles County and Vicinity; local health officials; Claudia Baquet, a doctor and specialist in health disparities at the University of Maryland School of Medicine; and state Sen. Continue reading ...

Royal Philips Electronics announced that it will lead a new European Union (EU) funded research project called 'euHeart', which is aimed at improving the diagnosis, therapy planning and treatment of cardiovascular disease - one of the biggest causes of mortality in the western world. Continue reading ...

Biogen Idec (Nasdaq: BIIB) announced the initiation of a Phase III clinical trial of intravenous (IV) ADENTRI® (BG9928), an adenosine A1 receptor antagonist, for acute decompensated heart failure (ADHF) patients with renal insufficiency. The trial will evaluate ADENTRI, which is being developed under a licensing agreement with CV Therapeutics (Nasdaq: CVTX), or placebo in addition to standard of care in approximately 900 patients in 21 countries globally, including the United States. Continue reading ...

It is the very early hours of the morning and you awake with a tightness in your chest. This uncomfortable pressure is making it difficult to breathe, and you feel lightheaded and nauseous. Your first instinct is to shrug off the fear that you might be having a heart attack and attribute your pain to heartburn from overindulging the night before or even food poisoning. Yet if you continue to avoid taking your pain and symptoms seriously, your life is at risk - and the clock is ticking. Continue reading ...

Women may safely discontinue oral anticoagulants (blood thinners) after 6 months of treatment following a first unprovoked venous blood clot (thromboembolism) if they have no or one risk factor, concludes a study of 646 participants in a multicentre prospective cohort study. Blood clots are common and a potentially fatal condition. Continue reading ...

Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event. Continue reading ...

Misdiagnosis of Cancer

There must be nothing worse for women to be told you have breast cancer and the only option is a mastectomy which involves the removal of a breast. Imagine how you would feel if you were told that you never had cancer in the first place and the mastectomy was completely unnecessary. Just the though of loosing a breast is scary in itself, but the thought of going through the emotional trauma of loosing a breast because of misdiagnosis is totally imaginable but must be must be completely horrendous.